UNSPSC 51282957: Ofloxacin hydrochloride

This classification denotes a quinolone antibiotic with the molecular formula C18H20FN3O4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I2UWV315WA. European Medicines Agency schedules ofloxacin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03494MIG. The term ofloxacin hydrochloride is a U.S. FDA designation. Most nations schedule ofloxacin hydrochloride under HS 29349990. As of Q4 2014, OFLOXACIN HYDROCHLORIDE remains the US FDA Preferred Term for this commodity.

SMILES: CC1COC2C3N1CC(C(=O)C3CC(C2N4CCN(CC4)C)F)C(=O)O.CL.

UNSPSC 51282957 Ofloxacin hydrochloride is a Commodity code for a specific pharmaceutical active ingredient. State and local governments procure this product primarily through piggyback contracts and cooperative purchasing agreements that bundle multiple pharmaceutical products for institutional supply — typically for public health departments, county health systems, and community health initiatives. The scope includes procurement of ofloxacin hydrochloride in finished dosage forms (tablets, capsules, or injectable formulations) through competitive bidding processes managed by state pharmaceutical consortia or county purchasing offices.

Recent activity shows limited direct solicitation under this code; the Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse contract through the MMCAP Infuse cooperative purchasing vehicle to Chartwell Rx LLC on August 28, 2026, but this award included related fluoroquinolone products (Ciprofloxacin Hydrochloride 500mg and Doxycycline Hyclate 100mg) rather than ofloxacin specifically. The award was made through an Invitation for Bid process with a 12-month initial term and two annual renewal options. Other state and local pharmaceutical procurements tagged to related antimicrobial categories have emerged from Florida county health systems, though these focus on naloxone and drug deactivation supplies rather than ofloxacin products. Geographic activity appears concentrated in Illinois and Florida, with procurement activity driven by state health department purchasing offices and county-level health agencies using cooperative purchasing consortia. The code shows modest current activity; firms pursuing pharmaceutical supply contracts should monitor MMCAP Infuse and equivalent state pharmaceutical cooperative agreements rather than expect standalone ofloxacin solicitations.